Jakavi 15 mg Ruxolitinib

Jakavi (ruxolitinib) is a specialized pharmaceutical product used for the treatment of certain blood disorders and cancers. The brand was the result of a collaborative development effort between the American biopharmaceutical company Incyte Corporation and the Swiss multinational Novartis. While Incyte holds the rights in the United States (where it is marketed as Jakafi), Novartis licensed the rights to market and distribute the drug internationally under the name Jakavi.

Manufacturing of Jakavi is primarily centered in Switzerland, leveraging Novartis's extensive high-tech production facilities, although global supply chains may involve secondary packaging or production sites in other European countries to meet regional demand. Novartis remains the ultimate owner for the international rights of the product, maintaining its headquarters in Basel, Switzerland, and operating as one of the world's largest pharmaceutical companies.